News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ACT Biotech Release: Telatinib Effect on Biomarker is Associated With More Than Six Months Improvement in Progression-Free Survival for Stomach Cancer Patients


11/14/2011 9:59:34 AM

SAN FRANCISCO, Nov. 12, 2011 (GLOBE NEWSWIRE) -- ACT Biotech, Inc., a clinical stage biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, announced that results from a Phase 2 gastric cancer trial of telatinib on biomarker response will be presented at the AACR-NCI-EORTC International Conference in San Francisco. The results demonstrate that patients who were treated with a combination regimen of telatinib, a potent and selective oral inhibitor of vascular endothelial growth factor receptor (VEGFR), capecitabine and cisplatin and who responded with a large decrease of a specific angiogenesis biomarker - the soluble form of VEGFR2 (sVEGFR2) - were found to have a lower risk of disease progression and death compared to patients with smaller decreases.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES